GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

COFCO Biotechnology Co 000930.SZ · CNY

Materials · Shenzhen · 🇨🇳 China

Compare

4.77

-0.42%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥17.51bn

FY2016FY2025

Net income

CN¥38.4m

FY2016FY2025

Free cash flow

CN¥1.17bn

FY2016FY2025

Shareholders' equity

CN¥10.61bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥17.51bnCN¥20.05bnCN¥20.38bnCN¥19.92bnCN¥23.56bnCN¥19.91bnCN¥19.47bnCN¥17.70bnCN¥15.89bnCN¥5.60bn
Gross profitCN¥1.46bnCN¥1.15bnCN¥581.4mCN¥2.08bnCN¥2.44bnCN¥1.82bnCN¥2.62bnCN¥2.76bnCN¥2.38bnCN¥734.9m
Research and developmentCN¥160.0mCN¥128.8mCN¥165.3mCN¥132.9mCN¥119.2mCN¥113.7mCN¥87.2mCN¥96.3mCN¥101.1mCN¥79.8m
Operating incomeCN¥142.8mCN¥71.5m−CN¥572.4mCN¥1.42bnCN¥1.52bnCN¥806.3mCN¥817.0mCN¥780.6mCN¥997.0mCN¥292.8m
Net incomeCN¥38.4mCN¥25.1m−CN¥601.6mCN¥1.06bnCN¥1.13bnCN¥593.1mCN¥592.8mCN¥483.0mCN¥929.3mCN¥127.1m
Diluted earnings per share0.020.01-0.320.570.620.320.320.260.200.13

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥16.77bnCN¥17.33bnCN¥16.56bnCN¥18.10bnCN¥18.06bnCN¥20.48bnCN¥17.16bnCN¥20.29bnCN¥5.96bnCN¥5.44bn
Cash and short-term investments—CN¥1.91bnCN¥1.48bnCN¥1.02bnCN¥1.12bnCN¥662.3mCN¥700.5mCN¥772.9mCN¥554.8mCN¥617.8m
Total liabilitiesCN¥5.75bnCN¥6.41bnCN¥5.70bnCN¥5.59bnCN¥6.30bnCN¥9.68bnCN¥6.95bnCN¥10.64bnCN¥3.99bnCN¥3.73bn
DebtCN¥367.8mCN¥4.34bnCN¥3.76bnCN¥3.23bnCN¥3.40bnCN¥6.83bnCN¥3.01bnCN¥5.80bnCN¥2.80bnCN¥2.50bn
Shareholders' equityCN¥10.61bnCN¥10.52bnCN¥10.45bnCN¥12.10bnCN¥11.40bnCN¥10.39bnCN¥9.83bnCN¥9.23bnCN¥1.80bnCN¥1.56bn
Shares outstanding1,852m1,904m1,873m1,854m1,831m1,855m1,846m1,889m4,536m967m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.85bnCN¥155.8mCN¥1.96bnCN¥708.4mCN¥4.84bn−CN¥2.91bnCN¥3.65bn−CN¥923.3mCN¥747.7mCN¥784.7m
Capital spending−CN¥673.9m−CN¥483.3m−CN¥634.5m−CN¥565.8m−CN¥1.11bn−CN¥987.5m−CN¥900.8m−CN¥868.4m−CN¥639.2m−CN¥160.5m
Free cash flowCN¥1.17bn−CN¥327.5mCN¥1.32bnCN¥142.7mCN¥3.73bn−CN¥3.90bnCN¥2.75bn−CN¥1.79bnCN¥108.4mCN¥624.2m
Dividends paid−CN¥83.1m−CN¥93.5m−CN¥1.17bn−CN¥457.0m−CN¥277.3m−CN¥29.9m−CN¥46.2m−CN¥191.5m−CN¥114.7m−CN¥131.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥4.32bnCN¥3.88bnCN¥4.25bnCN¥4.45bnCN¥4.43bnCN¥4.39bnCN¥4.93bnCN¥5.21bn
Gross profitCN¥187.9mCN¥221.5mCN¥348.6mCN¥460.3mCN¥300.2mCN¥354.2mCN¥20.2mCN¥515.4m
Operating incomeCN¥6.3mCN¥5.9mCN¥103.8m−CN¥47.3mCN¥114.1mCN¥73.1mCN¥29.2mCN¥20.6m
Net income−CN¥47.8m−CN¥121.4m−CN¥40.8m−CN¥28.1mCN¥66.7mCN¥40.5mCN¥15.5m−CN¥51.9m
Diluted earnings per share-0.03-0.07-0.02-0.020.040.020.01-0.03
Cash from operations———CN¥421.0mCN¥1.05bn−CN¥256.0m—CN¥1.16bn
Capital spending−CN¥356.0m−CN¥187.0m−CN¥221.0m−CN¥202.0m−CN¥126.0m−CN¥123.0m−CN¥171.0m−CN¥119.0m
Free cash flow———CN¥219.0mCN¥922.0m−CN¥379.0m—CN¥1.04bn
Total assetsCN¥18.04bnCN¥17.66bnCN¥16.77bnCN¥17.18bnCN¥17.76bnCN¥17.82bnCN¥17.33bnCN¥17.18bn
Cash and short-term investments———CN¥2.52bnCN¥2.39bnCN¥1.80bnCN¥1.91bnCN¥1.67bn
DebtCN¥1.30bnCN¥509.0mCN¥367.8mCN¥2.18bnCN¥4.26bnCN¥4.79bnCN¥4.16bnCN¥3.80bn
Shareholders' equityCN¥10.31bnCN¥10.41bnCN¥10.61bnCN¥10.66bnCN¥10.68bnCN¥10.57bnCN¥10.52bnCN¥10.51bn

Financial ratios

Data as of 3 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin8.4%5.7%2.9%10.4%10.3%9.1%
Operating margin1.0%0.4%-2.8%7.2%6.5%4.0%
Net margin0.2%0.1%-3.0%5.3%4.8%3.0%
Return on equity0.4%0.2%-5.8%8.7%9.9%5.7%
Return on assets0.2%0.1%-3.6%5.8%6.3%2.9%
Free cash flow yield26.4%6.5%26.8%13.3%63.0%-20.1%
Revenue growth-12.7%-1.6%2.3%-15.5%18.3%2.2%
Earnings growth52.7%-104.2%-156.8%-6.3%90.5%0.0%
Current ratio1.22x1.17x1.17x1.49x1.37x1.06x
Debt to equity0.03x0.40x0.34x0.25x0.28x0.65x
Equity ratio63.3%60.7%63.1%66.8%63.1%50.7%
Interest coverage1.96x0.66x-5.08x15.69x9.44x8.02x
R&D as a share of sales0.9%0.6%0.8%0.7%0.5%0.6%
Buybacks as a share of market value2.7%-1.7%-1.0%-1.2%1.3%-0.5%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-4.2%-2.5%10.5%
Operating income-53.5%-29.3%—
Net income-66.9%-42.2%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin6.9%6.8%7.9%9.6%
Operating margin0.6%1.4%2.8%2.5%
Net margin0.2%0.7%1.8%1.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings279.1420.6-20.714.617.626.320.629.065.1102.3
Price to sales0.60.50.60.80.80.80.60.83.82.3

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 3 Jul 2023.

FY2023FY2022FY2021FY2020FY2019FY2015FY2014FY2013
Paid in the year0.570.2450.0650.0160.0250.020.020.02
  • 2-for-1 split · 7 Dec 2005
  • 1-to-1 reverse split · 7 Nov 2005
  • 6-for-5 split · 19 Nov 2004
  • 9-for-5 split · 12 Jul 2002

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.